ROCKVILLE, Md. , Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024 .
Event Details For more information, please contact your Truist Securities representative. About I-Mab I-Mab (NASDAQ: IMAB ) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland , and Short Hills, New Jersey.
For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X .
For more information, please contact: Tyler Ehler Senior Director, Investor Relations [email protected] SOURCE I-Mab Biopharma.
